Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Cancer Discovery|September 5, 2020
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint BlockadeFrederick J Kohlhapp, Dipica Haribhai, Rebecca Mathew, et al.
Molecular Cancer Therapeutics|November 3, 2019
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Neoplasia (New York, N.Y.)|July 2, 2013
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responseDeepak Sampath, Jason Oeh, Shelby K Wyatt, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2022
Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenaseBinQing Wei, Kirk Robarge, Sharada S Labadie, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Cancer Discovery|September 5, 2020
Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint BlockadeFrederick J Kohlhapp, Dipica Haribhai, Rebecca Mathew, et al.
Molecular Cancer Therapeutics|November 3, 2019
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Neoplasia (New York, N.Y.)|July 2, 2013
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responseDeepak Sampath, Jason Oeh, Shelby K Wyatt, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinaseSteven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Journal of Medicinal Chemistry|January 11, 2014
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)Anthony M Giannetti, Xiaozhang Zheng, Nicholas J Skelton, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2022
Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenaseBinQing Wei, Kirk Robarge, Sharada S Labadie, et al.
Pageof 10